Drug Profile
Research programme: recombinant coagulation factors - CSL Behring
Alternative Names: CSL 626; CSL 650; CSL626 rD'D3-FP; rvWF-FPLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Blood coagulation factors; Recombinant fusion proteins
- Mechanism of Action Factor VIIa stimulants; Von Willebrand factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Haemophilia in USA (IV, Infusion)
- 28 Feb 2017 CSL 626 rD'D3-FP is in preclinical development for haemophilia (CSL group pipeline, February 2017)
- 03 Apr 2012 rvWF-FP is still in preclinical development for haemophilia in the US